Literature DB >> 3524169

The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure.

J G Cleland, H J Dargie, A Pettigrew, G Gillen, J I Robertson.   

Abstract

The effect of captopril as long-term treatment in 20 patients with congestive heart failure has been studied in a double-blind trial. Captopril caused a significant increase in serum digoxin levels. No patients developed evidence of digoxin toxicity. Serum and total body potassium rose and the frequency of ventricular arrhythmias showed a modest decline. Creatinine clearance and radioisotopically measured glomerular filtration rate fell, but there was a poor relationship between these and the increase in serum digoxin. In a further open study on 12 patients, creatinine, urea, and digoxin clearance were significantly reduced by captopril. However, digoxin clearance declined more than creatinine clearance (89 +/- 25 mumol/L to 69 +/- 22 mumol/L and 81 +/- 14 mumol/L to 72 +/- 19 mumol/L, respectively, p less than 0.05 for the difference). Fractional excretion of urea and digoxin filtered at the glomerulus declined, indicating greater tubular reabsorption or reduced tubular secretion of these compounds. Captopril causes an increase in serum digoxin by reducing renal clearance of the drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524169     DOI: 10.1016/0002-8703(86)90690-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Lack of effect of captopril on serum digoxin in congestive heart failure.

Authors:  C Magelli; L Bassein; M A Ribani; S Liberatore; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Increase of plasma digoxin levels after withdrawal from therapy in an elderly patient.

Authors:  Z Duraković
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

Review 3.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 4.  Fosinopril. Clinical pharmacokinetics and clinical potential.

Authors:  H Shionoiri; M Naruse; K Minamisawa; S Ueda; H Himeno; S Hiroto; I Takasaki
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 6.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 7.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 8.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 9.  Digoxin toxicity in the aged. Characterising and avoiding the problem.

Authors:  A P Passmore; G D Johnston
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

Review 10.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.